|
23 Feb 2021 |
Curocell announces Korean FDA clearance of the IND for CRC01, a first in kind immune checkpoint receptors downregulated CD19 CAR-T therapy
|
|
22 Feb 2021 |
Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer
|
|
20 Feb 2021 |
BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)
|
|
17 Feb 2021 |
Silence Therapeutics Initiates Dosing in Phase 1 Clinical Trial of SLN360 for Cardiovascular Disease Due to High Lipoprotein(a)
|
|
17 Feb 2021 |
Selecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR™ in Gene Therapy
|
|
16 Feb 2021 |
bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111)
|
|
16 Feb 2021 |
InteRNA Technologies Announces Dosing of First Patient in First-in-Human Trial of microRNA Drug Candidate INT-1B3 in Patients with Advanced Solid Tumors
|
|
14 Feb 2021 |
Gyroscope Therapeutics Announces Positive Interim Data from Phase I/II FOCUS Trial of Investigational Gene Therapy GT005
|
|
12 Feb 2021 |
Lysogene Receives FDA Clearance of Investigational New Drug Application to Initiate the Gene Therapy Clinical Trial in the US with LYS-GM101 for the Treatment of GM1 Gangliosidosis
|
|
11 Feb 2021 |
OliX Pharmaceuticals Announces Results from Preclinical Study of Hair Loss Therapeutic Candidate
|
|
11 Feb 2021 |
Mesoblast Phase 3 Trial Shows That a Single Injection of Rexlemestrocel-L + Hyaluronic Acid Carrier Results in at Least Two Years of Pain Reduction With Opioid Sparing Activity in Patients With Chronic Low Back Pain Due to Degenerative Disc Disease
|
|
10 Feb 2021 |
Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ for the Treatment of Prosthetic Joint Infections
|
|
10 Feb 2021 |
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
|
|
10 Feb 2021 |
Targovax and Papyrus Therapeutics enter research collaboration to develop novel ONCOS viruses with receptor tyrosine kinase (RTK) inhibitor functionality
|
|
10 Feb 2021 |
Tessa Therapeutics Announces Successful Dosing of First Patient Cohort in Phase I Allogeneic Cell Therapy Trial
|
|
10 Feb 2021 |
Taiga Treats First Cancer Patient in TBX-3400-003 Clinical Trial in Israel
|
|
10 Feb 2021 |
Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 2021 TCT Meetings of ASTCT and CIBMTR
|
|
10 Feb 2021 |
Launch of Novel Gene Therapy Company, VectorY, to Develop Innovative Vectorized Antibodies
|
|
10 Feb 2021 |
Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn’s Disease
|
|
09 Feb 2021 |
Tmunity Therapeutics Announces Expansion of T Cell Engineered Therapy Collaboration
|
|
09 Feb 2021 |
Orchard Therapeutics Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome (MPS-IH)
|
|
08 Feb 2021 |
FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare Pediatric Disorder with No Approved Disease-Modifying Treatment Options
|
|
08 Feb 2021 |
AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial
|
|
06 Feb 2021 |
Spark Therapeutics Announces Preliminary Data from Phase 1/2 Clinical Trial of SPK-8016 in Hemophilia A at EAHAD 2021 Virtual Congress
|
|
06 Feb 2021 |
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma
|
